Adeno-Associated Virus: The Naturally Occurring Virus Versus the Recombinant Vector

Human Gene Therapy

Volumn 27, Issue 1, 2016, Pages 1-6

  Srivastava, Arun ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS VECTOR;

ADENO ASSOCIATED VIRUS 2; DNA SYNTHESIS; HEMOPHILIA B; HUMAN; IMMUNE RESPONSE; INVERTED TERMINAL REPEAT; LIVER CELL; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PROTEIN PHOSPHORYLATION; REVIEW; UBIQUITINATION; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS GENOME; VIRUS RECOMBINANT; DEPENDOPARVOVIRUS; GENE THERAPY; GENE TRANSFER; GENE VECTOR; GENETICS; THERAPEUTIC USE;

DEPENDOVIRUS; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; HUMANS;

EID: 84955240212     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2015.29017.asr     Document Type: Review

References (44)

1. Manno CS, Pierce GF, Arruda VR, et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 2006;12:342-347.
2. Zhong L, Zhao W, Wu J, et al. A dual role of EGFR protein tyrosine kinase signaling in ubiquitination of AAV2 capsids and viral second-strand DNA synthesis. Mol Ther 2007;15:1323-1330.
3. Duan D, Yue Y, Yan Z, et al. Endosomal processing limits gene transfer to polarized airway epithelia by adeno-associated virus. J Clin Invest 2000; 105:1573-1587.
4. Zhong L, Li B, Mah CS, et al. Next generation of adeno-associated virus 2 vectors: Point mutations in tyrosines lead to high-efficiency transduction at lower doses. Proc Natl Acad Sci U S A 2008; 105:7827-7832.
5. Markusic DM, Herzog RW, Aslanidi GV, et al. Highefficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol Ther 2010;18: 2048-2056.
6. Martino AT, Basner-Tschakarjan E, Markusic DM, et al. Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsidspecific CD8+ T cells. Blood 2013;121:2224-2233.
7. Aslanidi GV, Rivers AE, Ortiz L, et al. Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold? PLoS One 2013;8:e59142.
8. Li B, Ma W, Ling C, et al. Site-directed mutagenesis of surface-exposed lysine residues leads to improved transduction by AAV2, but not AAV8, vectors in murine hepatocytes in vivo. Hum Gene Ther Methods 2015;26:211-220.
9. Guy J; National Eye Institute. Safety study of an adeno-associated virus vector for gene therapy of Leber's hereditary optic neuropathy (LHON). In: ClinicalTrials. gov [Internet]. Bethesda, MD: National Library of Medicine. 2014-[cited 2015 Dec 16]. Available from: https://clinicaltrials. gov/ct2/show/ NCT02161380 [NLM Identifier: NCT02161380].
10. Applied Genetic Technologies Corp. Safety and efficacy of rAAV-hRS1 in patients with X-linked retinoschisis (XLRS). In: ClinicalTrials. gov [Internet]. Bethesda, MD: National Library of Medicine. 2015-[cited 2015 Dec 16]. Available from: https:// clinicaltrials. gov/ct2/show/NCT02416622 [NLM Identifier: NCT02416622].
11. Applied Genetic Technologies Corp. Safety and efficacy trial of AAV gene therapy in patients with CNGB3 achromatopsia. In: ClinicalTrials. gov [Internet]. Bethesda, MD: National Library of Medicine. 2015-[cited 2015 Nov 5]. Available from: https://clinicaltrials. gov/cL2/show/NCT02599922 [NLM Identifier: NCT02599922].
12. Fisher KJ, Gao GP, Weitzman MD, et al. Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis. J Virol 1996;70:520-532.
13. Ferrari FK, Samulski T, Shenk T, et al. Secondstrand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors. J Virol 1996;70:3227-3234.
14. Zhong L, Zhou X, Li Y, et al. Single-polarity recombinant adeno-associated virus 2 vectormediated transgene expression in vitro and in vivo: mechanism of transduction. Mol Ther 2008;16: 290-295.
15. Zhou X, Zeng X, Fan Z, et al. Adeno-associated virus of a single-polarity DNA genome is capable of transduction in vivo. Mol Ther 2008;16:494-499.
16. Ponnazhagan S, Mukherjee P, Yoder MC, et al. Adeno-associated virus 2-mediated gene transfer in vivo: Organ-tropism and expression of transduced sequences in mice. Gene 1997;190:203-210.
17. Snyder RO, Miao CH, Patijn GA, et al. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors. Nat Genet 1997;16:270-276.
18. Qing K, Khuntirat B, Mah C, et al. Adeno-associated virus type 2-mediated gene transfer: correlation of tyrosine phosphorylation of the cellular singlestranded D sequence-binding protein with transgene expression in human cells in vitro and murine tissues in vivo. J Virol 1998;72:1593-1599.
19. McCarty DM, Monahan PE, and Samulski RJ. Selfcomplementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis. Gene Ther 2001;8:1248-1254.
20. Nathwani AC, Tuddenham EG, Rangarajan S, et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med 2011;365: 2357-2365.
21. Nathwani AC, Reiss UM, Tuddenham EG, et al. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med 2014;371: 1994-2004.
22. Lisowski L, Dane AP, Chu K, et al. Selection and evaluation of clinically relevant AAV variants in a xenograft liver model. Nature 2014;506:382-386.
23. Li S, Ling C, Zhong L, et al. Efficient and targeted transduction of nonhuman primate liver with systemically delivered optimized AAV3B vectors. Mol Ther 2015;23:1867-1876.
24. Wang L, Bell P, Somanathan S, et al. Comparative study of liver gene transfer with AAV vectors based on natural and engineered AAV capsids. Mol Ther 2015;23:1877-1887.
25. Bainbridge JW, Smith AJ, Barker SS, et al. Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med 2008;358: 2231-2239.
26. Maguire AM, Simonelli F, Pierce EA, et al. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med 2008;358:2240-2248.
27. Cideciyan AV, Aleman TS, Boye SL, et al. Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics. Proc Natl Acad Sci U S A 2008;105: 15112-15117.
28. Hauswirth WW, Aleman TS, Kaushal S, et al. Treatment of Leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adenoassociated virus gene vector: short-term results of a phase I trial. Hum Gene Ther 2008;19:979-990.
29. Stroes ES, Nierman MC, Meulenberg JJ, et al. Intramuscular administration of AAV1-lipoprotein lipase S447X lowers triglycerides in lipoprotein lipase-deficient patients. Arterioscler Thromb Vasc Biol 2008;28:2303-2304.
30. Hwu WL, Muramatsu S, Tseng SH, et al. Gene therapy for aromatic L-amino acid decarboxylase deficiency. Sci Transl Med 2012;4:134ra61.
31. MacLaren RE, Groppe M, Barnard AR, et al. Retinal gene therapy in patients with choroideremia: Initial findings from a phase 1/2 clinical trial. Lancet 2014;383:1129-1137.
32. Qing K, Wang XS, Kube DM, et al. Role of tyrosine phosphorylation of a cellular protein in adenoassociated virus 2-mediated transgene expression. Proc Natl Acad Sci U S A 1997;94:10879-10884.
33. Mah C, Qing K, Khuntirat B, et al. Adeno-associated virus type 2-mediated gene transfer: role of epidermal growth factor receptor protein tyrosine kinase in transgene expression. J Virol 1998;72:9835-9843.
34. Qing K, Li W, Zhong L, et al. Adeno-associated virus type 2-mediated gene transfer: role of cellular T-cell protein tyrosine phosphatase in transgene expression in established cell lines in vitro and transgenic mice in vivo. J Virol 2003;77:2741-2746.
35. Zhong L, Li W, Yang Z, et al. Improved transduction of primary murine hepatocytes by recombinant adeno-associated virus 2 vectors in vivo. Gene Ther 2004;11:1165-1169.
36. Zhong L, Chen L, Li Y, et al. Self-complementary adeno-associated virus 2 (AAV)-T cell protein tyrosine phosphatase vectors as helper viruses to improve transduction efficiency of conventional single-stranded AAV vectors in vitro and in vivo. Mol Ther 2004;10:950-957.
37. Jayandharan GR, Zhong L, Li B, et al. Strategies for improving the transduction efficiency of singlestranded adeno-associated virus vectors in vitro and in vivo. Gene Ther 2008;15:1287-1293.
38. Jayandharan GR, Zhong L, Sack BK, et al. Optimized adeno-associated virus (AAV)-protein phosphatase-5 helper viruses for efficient liver transduction by single-stranded AAV vectors: therapeutic expression of factor IX at reduced vector doses. Hum Gene Ther 2010;21:271-283.
39. Wang XS, Ponnazhagan S, and Srivastava A. Rescue and replication signals of the adenoassociated virus 2 genome. J Mol Biol 1995;250: 573-580.
40. Wang XS, Ponnazhagan S, and Srivastava A. Rescue and replication of adeno-associated virus type 2 as well as vector DNA sequences from recombinant plasmids containing deletions in the viral inverted terminal repeats: selective encapsidation of viral genomes in progeny virions. J Virol 1996;70:1668-1677.
41. Ling C, Wang, Y, Lu Y, et al. The adeno-associated virus genome packaging puzzle. J Mol Genet Med 2015;9: 175.
42. Jayandharan G, Aslanidi G, Martino AT, et al. Activation of the NF-jB pathway by adenoassociated virus (AAV) vectors and its implications in immune response and gene therapy. Proc Natl Acad Sci U S A 2011;108:3743-3748.
43. Ling C, Wang Y, Lu Y, et al. Enhanced transgene expression from recombinant single-stranded Dsequence-substituted adeno-associated virus vectors in human cell lines in vitro and in murine hepatocytes in vivo. J Virol 2015;89:952-961.
44. Naldini L. Gene therapy returns to centre stage. Nature 2015;526:351-360.